Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE (palbociclib) and talazoparib in Combination with CB-839
SAGA Metals Highlights Radar Titanium Opportunity as North America Confronts Defense Driven Titanium Supply Chain Risks
RETRANSMISSION: Blackrock Silver Closes C$15 Million Private Placement Led By a C$7 Million Investment from Eric Sprott
